Regeneron Pharmaceuticals, Inc.

Merck & Co’s PD-1 inhibitor for multiple cancer indications Keytruda (pembrolizumab) comfortably retained its number one spot as the drug generating the highest global revenues in the first quarte

Scholar Rock’s myostatin inhibitor apitegromab helped preserve lean mass in individuals taking Lilly’s GIP/GLP-1 agonist tirzepatide for weight loss in a Phase II trial, a new potentially large commer

Immuneering Corporation is planning a global pivotal trial in 2026 for atebimetinib in first-line pancreatic cancer after posting successful results of a Phase IIa study of the drug. Immuneering is ai

Eli Lilly and Verve Therapeutics agreed to a buyout on June 17 valued at approximately $1bn with a contingent value right (CVR) that could be attainable, bringing the total deal value to around $1.3bn